Rachel Neuwirth

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma

John P. Leonard, Kathryn S. Kolibaba, James A. Reeves et al. · Journal of Clinical Oncology · 2017 · 189 citations

Medicine, Hematology, Oncology +17

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens

Rubén Niesvizky, Ian W. Flinn, Robert M. Rifkin et al. · Journal of Clinical Oncology · 2015 · 152 citations

Medicine, Pharmacology, Pharmacotherapy +14

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

Martin H. Voss, Michael S. Gordon, Monica Mita et al. · British Journal of Cancer · 2020 · 90 citations · Full text

Medicine, Oncology, Pharmacology +12

Sustained Exposure to the Investigational Kisspeptin Analog, TAK-448, Down-Regulates Testosterone into the Castration Range in Healthy Males and in Patients With Prostate Cancer: Results From Two Phase 1 Studies

David B. MacLean, Hisanori Matsui, Ajit Suri et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 64 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours

Kathleen N. Moore, Todd M. Bauer, Gerald S. Falchook et al. · ESMO Open · 2018 · 45 citations · Full text

Pharmacy, Oncology, Pharmacology +13